Skip to Content

About Us
- Leadership
- Board of Directors
Our Approach
- Our Approach
- Scientific Publications
Pipeline
Investors & Media
Partnerships
Careers

Press Releases

Year

06.14.21

Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH

06.13.21

Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment of NASH

05.19.21

Terns to Present at the UBS Global Healthcare Virtual Conference & Participate in the J.P. Morgan Biotech 2021 CEO Conference Call Series

05.13.21

Terns Reports First Quarter 2021 Financial Results and Provides Corporate Update

04.7.21

Terns to Present at the 19th Annual Virtual Needham HealthCare Conference

03.30.21

Terns Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

03.22.21

Terns Announces Initiation of Dosing in Phase 1 Clinical Trial of TERN-501, its THR-Beta Agonist in Development for the Treatment of NASH

03.8.21

Terns to Present on VAP-1 and FXR at NASH-TAG Conference 2021

02.23.21

Terns to Present at the Cowen 41st Annual Healthcare Conference

02.10.21

Terns Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Pagination

Current page 1
Page 2
Next page
Last page

TERNS
1065 East Hillsdale Blvd., Suite 100
Foster City, CA 94404 (MAP)
info@ternspharma.com
investors@ternspharma.com
media@ternspharma.com
Phone: +1 650-525-5535 Ext.101
Fax: +1 650-275-4395

Site - Social

Site - Corporate

About Us
Our Approach
Pipeline
Investors & Media
Partnerships
Careers
Contact Us

© 2021 Terns Pharmaceuticals, Inc. Privacy Policy